Q-GESIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for Q-GESIC (Q-GESIC).
Q-GESIC is a centrally acting non-opioid analgesic; its exact mechanism is unknown but may involve inhibition of cyclooxygenase (COX) and modulation of descending serotonergic and noradrenergic pathways.
| Metabolism | Hepatic via CYP450 (CYP1A2 and CYP2D6) and glucuronidation. |
| Excretion | Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; <5% metabolized via CYP enzymes. |
| Half-life | Terminal elimination half-life is 2-4 hours; clinical context: requires dosing every 4-6 hours for sustained analgesia. |
| Protein binding | Approximately 95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 2-3 L/kg; indicates extensive tissue distribution with accumulation in inflamed tissues. |
| Bioavailability | Oral: 70-80% due to first-pass metabolism; Intramuscular: 90-100%; Intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-10 minutes; Intramuscular: 10-20 minutes. |
| Duration of Action | Analgesic effect lasts 4-6 hours after oral or intramuscular administration; intravenous duration is shorter at 2-3 hours. |
1-2 tablets (325-650 mg acetaminophen and 5-10 mg hydrocodone) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: Administer every 6 hours; maximum 5 tablets daily. GFR 10-29 mL/min: Administer every 8 hours; maximum 4 tablets daily. GFR <10 mL/min: Not recommended. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% and extend interval to every 8 hours; maximum 4 tablets daily. Child-Pugh Class C: Avoid use. |
| Pediatric use | Weight-based dosing for hydrocodone: 0.1-0.2 mg/kg/dose every 4-6 hours as needed; maximum 6 doses per day. For acetaminophen: 10-15 mg/kg/dose every 4-6 hours; maximum 75 mg/kg/day. Not recommended in children <2 years. |
| Geriatric use | Initiate with lowest dose (1 tablet every 6 hours) and titrate cautiously due to increased risk of respiratory depression, falls, and acetaminophen hepatotoxicity. Maximum 6 tablets daily. Avoid in frail elderly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for Q-GESIC (Q-GESIC).
| Breastfeeding | Excreted in breast milk in low amounts; M/P ratio not established. Manufacturer recommends caution due to potential adverse effects on infant renal function and platelet aggregation. |
| Teratogenic Risk | First trimester: Limited human data; animal studies suggest skeletal abnormalities at high doses. Second/Third trimesters: Risk of premature ductus arteriosus closure and oligohydramnios with NSAID use; avoid after 30 weeks gestation. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to any component; severe hepatic impairment; use of MAO inhibitors within 14 days.
| Precautions | Hepatotoxicity with overdose or chronic use; severe skin reactions (SJS/TEN); hypersensitivity reactions; avoid with severe hepatic impairment. |
Loading safety data…
| Monitor amniotic fluid index if used beyond 20 weeks; fetal echocardiography if used after 30 weeks for ductus arteriosus patency. Maternal renal function and bleeding time assessment. |
| Fertility Effects | Reversible inhibition of ovulation; may delay time to pregnancy. No evidence of permanent infertility. |